Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

IFNα has been used to treat malignant and viral disorders for more than 25 years. Its efficacy
is likely the consequence of its broad range of biologic activities, including direct effects on …

Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal
chromosomal translocation between chromosomes 9 and 22 [t (9; 22)], producing the Bcr …

In a proportion of patients with chronic myeloid leukemia (CML) being treated with dasatinib,
we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell …

To date, five cancer treatment modalities have been defined. The three traditional modalities
of cancer treatment are surgery, radiotherapy, and conventional chemotherapy, and the two …

Platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) represent one of the
most intensively studied families of growth factors in the last four decades. PDGF signaling …

The addition of interferon to tyrosine kinase inhibitors (TKIs), to improve deep molecular
response (DMR) and potentially treatment‐free remission (TFR) rates in chronic‐phase …

Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given
patients hope for a long disease-free-survival. A longer survival raises the question of late …

Pathogenesis of chronic graft-versus-host disease (cGVHD) is incompletely defined,
involving donor-derived CD4 and CD8-positive T lymphocytes as well as B cells. Standard …

Simple Summary Chronic myeloid leukemia (CML) is a blood cancer. Unlike other cancers
CML treatment is lifelong and many patients experience side effects. For those patients who …